Mission Bio appoints Robert Ghenchev to its Board along with raising $70m Series C funding led by Novo Growth

– USA, CA –  Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced $70 million in its Series C financing led by Novo Growth, the growth equity arm of Novo Holdings alongside Soleus Capital which also joins the round, along with earlier investors Mayfield, Cota, and Agilent, bringing the total funding to more than $120 million.…

Disc Medicine announces Donald Nicholson to its Board along with raising $50m Series A financing led by Novo Holdings

– USA, MA –  Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic diseases, today announced the completion of a $50 million Series A financing led by Novo Holdings A/S along with Access Biotechnology and founding investor Atlas Venture that seeded the company in 2017.…

Cyteir Therapeutics adds Dr Karen Hong to its Board along with announcing $40m Series B financing led by Novo Holdings

– USA, MA –  Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies for cancer, today announced the close of an additional $40.2 million Series B financing, for a total of $75.2 million in this financing led by Novo Holdings, joined by existing investors Venrock, DROIA Oncology Ventures, Osage University Partners (OUP), Lightstone Ventures and Celgene Corporation.…